{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:40:06Z","timestamp":1779237606308,"version":"3.51.4"},"reference-count":12,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,1,2]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>A 70-year-old man with medical history of IgG kappa multiple myeloma, initially diagnosed in 2017, underwent induction therapy with carfilzomib, lenalidomide and dexamethasone followed by autologous haematopoietic stem cell transplantation. Nine months following transplant, disease relapsed in the form of plasma cell leukaemia. Fluorescent in situ hybridisation of malignant plasma cells revealed t(11;14). A combination therapy including venetoclax was used based on efficacy data for Bcl-2 inhibitor venetoclax from available early-phase clinical trials in patients with relapsed multiple myeloma with t(11;14) and other published case studies. Unfortunately, the disease was primary refractory, and after further ineffective therapies, the patient did not have a successful outcome.<\/jats:p>","DOI":"10.1136\/bcr-2020-238641","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T11:43:52Z","timestamp":1611575032000},"page":"e238641","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Plasma cell leukaemia with t(11;14) not responsive to venetoclax"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-1064","authenticated-orcid":false,"given":"Mohammed Isaac","family":"Abu Zaanona","sequence":"first","affiliation":[{"name":"Internal Medicine, Carle Foundation Hospital, Urbana, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyank","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Hematology & Oncology, Carle Foundation Hospital, Urbana, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"2025082801573091000_14.1.e238641.1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.336"},{"key":"2025082801573091000_14.1.e238641.2","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-019-0754-x","article-title":"Plasma cell leukemia: definition, presentation, and treatment","volume":"21","author":"Gundesen","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2025082801573091000_14.1.e238641.3","doi-asserted-by":"crossref","unstructured":"An G , Xu Y , Shi L . T(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk Res 2013.","DOI":"10.1016\/j.leukres.2013.06.020"},{"key":"2025082801573091000_14.1.e238641.4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17474086.2018.1548931","article-title":"Venetoclax for the treatment of multiple myeloma","volume":"11","author":"Vaxman","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"2025082801573091000_14.1.e238641.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786"},{"key":"2025082801573091000_14.1.e238641.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788323"},{"key":"2025082801573091000_14.1.e238641.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.09.046","article-title":"A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"19","author":"Kumar","year":"2019","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"2025082801573091000_14.1.e238641.8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bjh.16454","article-title":"Real-world data on safety and efficacy of venetoclax-based regimens in relapsed\/refractory t(11;14) multiple myeloma","volume":"189","author":"Basali","year":"2020","journal-title":"Br J Haematol"},{"key":"2025082801573091000_14.1.e238641.9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ejh.12986","article-title":"Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025082801573091000_14.1.e238641.10","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1002\/ajh.25676","article-title":"The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia","volume":"95","author":"Nalghranyan","year":"2020","journal-title":"Am J Hematol"},{"key":"2025082801573091000_14.1.e238641.11","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/ajh.25331","article-title":"Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)","volume":"94","author":"Jelinek","year":"2019","journal-title":"Am J Hematol"},{"key":"2025082801573091000_14.1.e238641.12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/1078155219895072","article-title":"A successful case of venetoclax-based therapy in relapsed\/refractory secondary plasma cell leukemia","volume":"26","author":"Kupsh","year":"2020","journal-title":"J Oncol Pharm Pract"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-238641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:57:41Z","timestamp":1756371461000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-238641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,25]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/bcr-2020-238641"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-238641","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}